早期切除非小细胞肺癌辅助化疗四项试验中TP53与KRAS或EGFR共突变状态预后及预测作用的汇总分析
该汇总分析纳入四项辅助化疗随机试验的3533例非小细胞肺癌患者,其中1181例(557例死亡)用于TP53/KRAS分析,404例(170例死亡)用于TP53/EGFR分析。TP53/KRAS共突变无预后效应(P=0.61),但化疗对其有边缘性预测效应(P=0.04),TP53/KRAS共突变者化疗较野生型/野生型有害(HR 2.49,95%CI 1.10-5.64,P=0.03)。腺癌中TP53/EGFR共突变既无预后(P=0.83)也无显著预测作用(P=0.86)。
要点
- TP53/KRAS共突变无预后效应(P=0.61),对化疗有边缘性预测效应(P=0.04)。
- TP53/KRAS共突变者辅助化疗较野生型/野生型有害(HR 2.49,95%CI 1.10-5.64,P=0.03)。
- 腺癌中TP53/EGFR共突变无预后(P=0.83)及显著预测作用(P=0.86)。
核心结论
- 未发现KRAS或EGFR驱动基因与TP53抑癌基因共突变的预后效应。
- TP53/KRAS共突变对化疗的潜在负向预测效应需验证。
研究设计与样本
- 汇总分析四项辅助化疗对比观察的随机试验,纳入3533例非小细胞肺癌患者。
- TP53、KRAS、EGFR突变分析由多个实验室以盲法完成。
- 主要终点为总生存,次要终点为无病生存。
- 采用按试验分层的多变量Cox比例风险模型评估TP53/KRAS共突变(全部患者及腺癌亚组)和TP53/EGFR共突变(仅腺癌)。
主要发现
- TP53/KRAS分析纳入1181例(557例死亡),TP53/EGFR分析纳入404例(170例死亡)。
- TP53/KRAS突变状态无预后效应(P=0.61),有边缘性预测效应(P=0.04)。
- TP53/KRAS共突变者化疗较野生型/野生型有害(HR 2.49,95%CI 1.10-5.64,P=0.03)。
- 腺癌中TP53/EGFR共突变无预后(P=0.83)也无显著预测作用(P=0.86)。
- 两组的无病生存结果相似。
局限性
- TP53/KRAS共突变对化疗的潜在负向预测效应需验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Our previous work evaluated individual prognostic and predictive roles of TP53, KRAS, and EGFR in non-small-cell lung cancer (NSCLC). In this analysis, we explore the prognostic and predictive roles of TP53/KRAS and TP53/EGFR comutations in randomized trials of adjuvant chemotherapy versus observation. Patients and Methods Mutation analyses (wild-type [WT] and mutant) for TP53, KRAS, and EGFR were determined in blinded fashion in multiple laboratories. Primary and secondary end points of pooled analysis were overall survival and disease-free survival. We evaluated the role of TP53/KRAS comutation in all patients and in the adenocarcinoma subgroup as well as the TP53/EGFR comutation in adenocarcinoma only through a multivariable Cox proportional hazards model stratified by trial. Results Of 3,533 patients with NSCLC, 1,181 (557 deaths) and 404 (170 deaths) were used for TP53/KRAS and TP53/EGFR analyses. For TP53/KRAS mutation status, no prognostic effect was observed ( P = .61), whereas a borderline predictive effect ( P = .04) was observed with a deleterious effect of chemotherapy with TP53/KRAS comutations versus WT/WT (hazard ratio, 2.49 [95% CI, 1.10 to 5.64]; P = .03). TP53/EGFR comutation in adenocarcinoma was neither prognostic ( P = .83), nor significantly predictive ( P = .86). Similar results were observed for both groups for disease-free survival. Conclusion We could identify no prognostic effect of the KRAS or EGFR driver and TP53 tumor suppressor comutation. Our observation of a potential negative predictive effect of TP53/KRAS comutation requires validation.
引用
- Shepherd FA, Lacas B, Le Teuff G, et al. Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. J Clin Oncol. 2017. PMID: 28453411. doi:10.1200/JCO.2016.71.2893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。